Abstract
Although the impressive progression of modern diagnostic opportunities and therapeutic options, cardiovascular diseases still represent the leading causes of morbidity and mortality, worldwide. Beyond the effective pharmacological treatment of major cardiovascular disease or sequelae, however, cardiovascular diseases developing in adult individuals are largely preventable. The substantial failure to prevent cardiovascular disease in the 20th century generation is mostly linked to the ineffective use, as well as to the underuse of available preventive strategies. As a consequence, preventive strategies should be encouraged at both individual and population level, to substantially improve healthy status of the general population and reduce the burden of cardiovascular diseases in Western and Developing Countries.
Keywords: Cardiovascular disease, cardiovascular prevention, cardiovascular risk factors, high-risk individuals
Current Vascular Pharmacology
Title:Global Cardiovascular Risk Management in Primary Prevention
Volume: 10 Issue: 6
Author(s): Massimo Volpe and Giuliano Tocci
Affiliation:
Keywords: Cardiovascular disease, cardiovascular prevention, cardiovascular risk factors, high-risk individuals
Abstract: Although the impressive progression of modern diagnostic opportunities and therapeutic options, cardiovascular diseases still represent the leading causes of morbidity and mortality, worldwide. Beyond the effective pharmacological treatment of major cardiovascular disease or sequelae, however, cardiovascular diseases developing in adult individuals are largely preventable. The substantial failure to prevent cardiovascular disease in the 20th century generation is mostly linked to the ineffective use, as well as to the underuse of available preventive strategies. As a consequence, preventive strategies should be encouraged at both individual and population level, to substantially improve healthy status of the general population and reduce the burden of cardiovascular diseases in Western and Developing Countries.
Export Options
About this article
Cite this article as:
Volpe Massimo and Tocci Giuliano, Global Cardiovascular Risk Management in Primary Prevention, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520729
DOI https://dx.doi.org/10.2174/157016112803520729 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design The Role of the Novel Adipocyte-Derived Protein Adiponectin in Human Disease: An Update
Mini-Reviews in Medicinal Chemistry The Metabolic Syndrome and Cardiovascular Risk
Current Diabetes Reviews The Role of Brain Gaseous Transmitters in the Regulation of the Circulatory System
Current Pharmaceutical Biotechnology How Effective are the Lipid Modifying Medicines at Preventing Coronary Heart Disease in Patients with the Metabolic Syndrome?
Vascular Disease Prevention (Discontinued) Anesthetic Considerations for Electroconvulsive Therapy-Especially Hemodynamic and Respiratory Management
Current Psychiatry Reviews The Effects of Pemafibrate in Japanese Patients with Type 2 Diabetes Receiving HMG-CoA Reductase Inhibitors
Endocrine, Metabolic & Immune Disorders - Drug Targets Effects of Lipid-Lowering Agents on Inflammation, Haemostasis and Blood Pressure
Current Pharmaceutical Design C-11 Radiochemistry in Cancer Imaging Applications
Current Topics in Medicinal Chemistry Infection, Infectious Agents and Vascular Disease
Reviews on Recent Clinical Trials Novel Anti-arrhythmic Medications in the Treatment of Atrial Fibrillation
Current Cardiology Reviews Antiplatelet Treatment in Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Nitric Oxide Synthases and Their Natural Inhibitors
Current Enzyme Inhibition B-Type Natriuretic Peptide for Diagnosis and Therapy
Recent Patents on Cardiovascular Drug Discovery Beta-Blockers (Carvedilol) in Children with Systemic Ventricle Systolic Dysfunction - Systematic Review and Meta-Analysis
Reviews on Recent Clinical Trials Oxidative Stress in Diabetic Nephropathy
Current Medicinal Chemistry Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets The Killing of Human Neuroblastoma Cells by the Small Molecule JQ1 Occurs in a p53-Dependent Manner
Anti-Cancer Agents in Medicinal Chemistry Seaweed Proteins as a Source of Bioactive Peptides
Current Pharmaceutical Design Effects of Metabolic Approach in Diabetic Patients with Coronary Artery Disease
Current Pharmaceutical Design